Onderneming Pluristem Therapeutics Inc. Nasdaq
Aandelen
US72940R1023
Biotechnologie & Medisch Onderzoek
Vakgebied
Verkoop per activiteit
USD in miljoen | 2022 | Gewicht | 2023 | Gewicht | Delta |
---|---|---|---|---|---|
Placenta-Based Cell Therapy
100,0
%
| 0 | 100,0 % | 0 | 100,0 % | +22,65% |
Verkoop per regio
USD in miljoen | 2022 | Gewicht | 2023 | Gewicht | Delta |
---|---|---|---|---|---|
Israel
100,0
%
| 0 | 100,0 % | 0 | 100,0 % | +22,65% |
Managers
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Yaky Yanay
CEO | Chief Executive Officer | 52 | 01-11-06 |
Director of Finance/CFO | 40 | 01-05-13 | |
Zami Aberman
CHM | Chairman | 70 | 26-09-05 |
Artur Machlenkin
CTO | Chief Tech/Sci/R&D Officer | - | 01-05-22 |
Nitsan Halevy
CTO | Chief Tech/Sci/R&D Officer | - | 01-03-21 |
Lior Raviv
CTO | Chief Tech/Sci/R&D Officer | - | 01-01-11 |
Orly Amiran
PRN | Corporate Officer/Principal | - | - |
Nimrod Bar Zvi
PRN | Corporate Officer/Principal | - | - |
Efrat Kaduri
PRN | Corporate Officer/Principal | - | 01-10-14 |
Human Resources Officer | 62 | 01-01-07 |
Besturend
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Director/Board Member | 73 | 15-07-21 | |
Lorne Abony
BRD | Director/Board Member | 55 | 11-07-23 |
Zami Aberman
CHM | Chairman | 70 | 26-09-05 |
Yaky Yanay
CEO | Chief Executive Officer | 52 | 01-11-06 |
Director/Board Member | 54 | 06-01-21 | |
Director/Board Member | 61 | 01-06-21 |
Aandelenklasse
Stemming | Aantal | Vrij verhandelbaar | Bedrijfseigen aandelen | Drijvend Totaal | |
---|---|---|---|---|---|
Aandeel A | 1 | 5 388 792 | 4 101 934 ( 76,12 %) | 0 | 76,12 % |
Bedrijfsgegevens
Pluri, Inc.
MATAM Advanced Technology Park Building No. 5
3508409, Haifa
+972 74 710 8600
http://www.pluri-biotech.comSector
Vaira. 1 jan. | Kapi. | |
---|---|---|
+17,96% | 44,96 mld. | |
+1,17% | 42,65 mld. | |
+48,77% | 41,85 mld. | |
-4,27% | 29,04 mld. | |
+11,42% | 26,08 mld. | |
-21,39% | 19,03 mld. | |
+4,86% | 12,75 mld. | |
+27,29% | 12,06 mld. | |
-3,50% | 11,75 mld. |